secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001023024-23-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q2 revenue $116.5M (+57.8% YoY); raises FY2023 guidance
------------------------------------------------------------------

- Record Q2 net revenues of $116.5M (up 57.8% YoY); GAAP diluted EPS $0.29 vs $(0.94) loss in Q2 2022.
- Adjusted non-GAAP EBITDA $34.1M (up 246% YoY); adjusted diluted EPS $1.28 vs $0.13.
- Cortrophin Gel net sales $24.3M (+138.2% YoY); record new patient starts and prescribers.
- Raised FY2023 guidance: net revenue $425M-$445M (from $385M-$410M); adj. EBITDA $115M-$125M.
- Ended Q2 with $161.7M cash; completed equity offering with $80.6M net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/0001023024-23-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/ani-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001023024-23-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer